Advanced-stage Pancreatic Cancer: Therapy Options

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2013 May 1

PMID 23629472

Citations 112

Authors

Jens Werner

Stephanie E Combs

Christoph Springfeld

Werner Hartwig

Thilo Hackert

Markus W Buchler

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical resection is a requirement for a potential cure. However, the majority of patients are diagnosed with advanced-stage disease, either metastatic (50%) or locally advanced cancer (30%). Although palliative chemotherapy is the standard of care for patients with metastatic disease, management of locally advanced adenocarcinoma is controversial. Several treatment options, including extended surgical resections, neoadjuvant therapy with subsequent resections, as well as palliative radiotherapy and/or chemotherapy, should be considered. However, there is little evidence available to support treatment options for locally advanced disease. As valid predictive biomarkers for stratification of therapy are not available today, future trials need to define the role of the different treatment options. This Review summarizes the current evidence and discusses available treatment options for both locally advanced and metastatic pancreatic adenocarcinoma.

Citing Articles

Development of an efficient NUPR1 inhibitor with anticancer activity.

Liu X, Jimenez-Alesanco A, Li Z, Rizzuti B, Neira J, Estaras M Sci Rep. 2024; 14(1):29515.

PMID: 39604425 PMC: 11603058. DOI: 10.1038/s41598-024-79340-z.

Innovative theranostic hydrogels for targeted gastrointestinal cancer treatment.

Tang M, Song J, Zhang S, Shu X, Liu S, Ashrafizadeh M J Transl Med. 2024; 22(1):970.

PMID: 39465365 PMC: 11514878. DOI: 10.1186/s12967-024-05749-9.

CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment.

Tao J, Gu Y, Zhang Z, Weng G, Liu Y, Ren J J Exp Clin Cancer Res. 2024; 43(1):277.

PMID: 39358777 PMC: 11448066. DOI: 10.1186/s13046-024-03201-w.

Mutational profiling of 103 unresectable pancreatic ductal adenocarcinomas using EUS-guided fine-needle biopsy.

Buchberg J, de Stricker K, Pfeiffer P, Mortensen M, Detlefsen S Endosc Ultrasound. 2024; 13(3):154-164.

PMID: 39318643 PMC: 11419524. DOI: 10.1097/eus.0000000000000072.

Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.

Haller S, Essani K Biomedicines. 2024; 12(8).

PMID: 39200298 PMC: 11351728. DOI: 10.3390/biomedicines12081834.

References

Hosein P, Macintyre J, Kawamura C, Maldonado J, Ernani V, Loaiza-Bonilla A . A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012; 12:199. PMC: 3404979. DOI: 10.1186/1471-2407-12-199. View

Haddock M, Swaminathan R, Foster N, Hauge M, Martenson J, Camoriano J . Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol. 2007; 25(18):2567-72. DOI: 10.1200/JCO.2006.10.2111. View

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B . Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-7. PMC: 3148940. DOI: 10.1038/nature09515. View

Van Cutsem E, Vervenne W, Bennouna J, Humblet Y, Gill S, Van Laethem J . Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27(13):2231-7. DOI: 10.1200/JCO.2008.20.0238. View

Sohn T, Lillemoe K, Cameron J, Huang J, Pitt H, Yeo C . Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg. 1999; 188(6):658-66; discussion 666-9. DOI: 10.1016/s1072-7515(99)00049-6. View

Scorsetti M, Bignardi M, Alongi F, Fogliata A, Mancosu P, Navarria P . Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: feasibility and clinical preliminary results. Acta Oncol. 2011; 50(4):528-38. DOI: 10.3109/0284186X.2011.558522. View

Combs S, Jakel O, Haberer T, Debus J . Particle therapy at the Heidelberg Ion Therapy Center (HIT) - Integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiother Oncol. 2010; 95(1):41-4. DOI: 10.1016/j.radonc.2010.02.016. View

Varadhachary G, Tamm E, Abbruzzese J, Xiong H, Crane C, Wang H . Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8):1035-46. DOI: 10.1245/ASO.2006.08.011. View

Hackert T, Werner J, Weitz J, Schmidt J, Buchler M . Uncinate process first--a novel approach for pancreatic head resection. Langenbecks Arch Surg. 2010; 395(8):1161-4. DOI: 10.1007/s00423-010-0663-9. View

10.

Klaassen D, MacIntyre J, Catton G, Engstrom P, MOERTEL C . Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985; 3(3):373-8. DOI: 10.1200/JCO.1985.3.3.373. View

11.

Bilimoria K, Bentrem D, Ko C, Stewart A, Winchester D, Talamonti M . National failure to operate on early stage pancreatic cancer. Ann Surg. 2007; 246(2):173-80. PMC: 1933550. DOI: 10.1097/SLA.0b013e3180691579. View

12.

Butturini G, Stocken D, Wente M, Jeekel H, Klinkenbijl J, Bakkevold K . Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008; 143(1):75-83. DOI: 10.1001/archsurg.2007.17. View

13.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

14.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R . Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2012; 31(1):23-9. DOI: 10.1200/JCO.2012.44.4869. View

15.

Von Hoff D, Ramanathan R, Borad M, Laheru D, Smith L, Wood T . Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29(34):4548-54. PMC: 3565012. DOI: 10.1200/JCO.2011.36.5742. View

16.

Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S . A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009; 101(6):908-15. PMC: 2743365. DOI: 10.1038/sj.bjc.6605256. View

17.

Evans D, Rich T, Byrd D, Cleary K, Connelly J, Levin B . Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127(11):1335-9. DOI: 10.1001/archsurg.1992.01420110083017. View

18.

Kindler H, Ioka T, Richel D, Bennouna J, Letourneau R, Okusaka T . Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011; 12(3):256-62. DOI: 10.1016/S1470-2045(11)70004-3. View

19.

van Heek N, van Geenen R, Busch O, Gouma D . Palliative treatment in "peri"-pancreatic carcinoma: stenting or surgical therapy?. Acta Gastroenterol Belg. 2002; 65(3):171-5. View

20.

Gradishar W . Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006; 7(8):1041-53. DOI: 10.1517/14656566.7.8.1041. View